Erwan Donal
Prof Erwan Donal is an expert in Cardiology at Centre Hospitalier Universitaire de Rennes (France). As of October 2026, ScienceLeadR ranks Erwan Donal in the top 1% of experts worldwide for Tricuspid Valve Insufficiency, Transthyretin amyloidosis and Mitral Valve Insufficiency. Erwan Donal has authored 1,109 publications, the most recent in 2026, and is an investigator in 65 clinical trials, 20 of them ongoing. SLR score: 4,808 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Medical Imaging - Public Health - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1997 - 2026
Number : 1109
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| AI-assisted handheld echocardiography for hospital bedside cardiac triage: The prospective OPTIMUST implementation study. PMID 42749085 — safety, triage, workflow, cardiology, physicians, echocardiography, artificial intelligence | Int J Cardiol | 2026 | 1 |
| Genetic susceptibility in Takotsubo syndrome: a candidate gene association analysis in the French TAKOGENE cohort. PMID 42863705 — genes, stress, physiological, genetic predisposition to disease, population control, sex, polymorphism, single nucleotide, genetic diseases, inborn, cardiomyopathies, takotsubo cardiomyopathy | Eur J Med Genet | 2026 | 0 |
| Rivaroxaban for Stroke Prevention in Hypertrophic Cardiomyopathy Without Atrial Fibrillation and With Impaired Left Atrial Reservoir Strain: Design and Rationale of the LA-HCM Randomized Trial. PMID 42844166 — stroke, rivaroxaban, atrial fibrillation, cardiomyopathy, hypertrophic, cardiomyopathies | Eur Heart J Cardiovasc Imaging | 2026 | 0 |
| Impact of Tricuspid Regurgitation on Outcomes After Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation: The PRIME-MR Registry. PMID 42723620 — registries, mortality, cardiovascular surgical procedures, heart failure, tricuspid valve insufficiency, mitral valve insufficiency | Circ Cardiovasc Interv | 2026 | 0 |
| Recommended Criteria to Define Right Ventricular Dysfunction in Severe Secondary Tricuspid Regurgitation: Association With Outcome. PMID 42720641 — ventricular dysfunction, ventricular dysfunction, right, tricuspid valve, tricuspid valve insufficiency, ventricular function, right | JACC Cardiovasc Imaging | 2026 | 1 |
Clinical Studies 65
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 14
Ongoing Clinical Trials
20 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| CLEOPATTRA A research study to look at the effects of treatment with a medicine called coramitug (NNC6019 0001) in people with heart failure due to ATTR amyloidosis 2024-518899-31-00 — heart failure, heart, prealbumin, amyloidosis, research, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | Phase 3 | Recruiting | 2025 |
| A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy 2024-518343-38-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis | Phase 3 | Active not recruiting | 2025 |
| ATHENA A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation 2023-506988-34-00 — heart failure, heart, signs and symptoms, research | Phase 3 | Active not recruiting | 2024 |
| A study to determine if ALXN2220 is effective safe and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR CM) 2023-506669-70-00 — safety, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | Phase 3 | Active not recruiting | 2024 |
| TRITON CM A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy 2024-519917-72-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis | Phase 3 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map